Cell-based treatments are using regenerative medicine to help grow the heart muscle in people with HLHS. These cell-based therapies are currently being developed and could restore the pumping function of the right ventricle once it begins to decline or prevent the decline altogether. There are open clinical trials that offer the latest advancements in cell therapy to people with HLHS. These clinical trials vary by age and treatment. For more information, view a list of the studies or send an email to the HLHS study coordinators of the Todd and Karen Wanek Family Program for HLHS.
Imaging and Outcomes
Every day, physicians and researchers are studying the long-term effects of single-ventricular performance in people with HLHS. By comparing the medical histories of HLHS patients using ultrasound and MRI images, they are able to noninvasively detect the heart’s performance. These imaging tools help determine a possible decline in heart function as early as possible in order to better manage treatment options.
While researchers believe HLHS can be attributed to a genetic cause, specific genes have not yet been identified. Investigators are looking at whole genome sequencing and bioinformatics analyses to search for HLHS genetic variations. To do this, they rely on family research participants to study each family’s genomes.
If you are interested in learning more about the research in these many areas, contact HLHS study coordinators of the Todd and Karen Wanek Family Program for HLHS .